Related Experiment Video
Updated: May 13, 2025
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
The Decline and Fall of the Current Chemotherapy Paradigm in Soft Tissue Sarcoma
John Rieth1, Varun Monga2, Mohammed Milhem1
1Holden Comprehensive Cancer Center, University of Iowa Health Care, Iowa City, IA 52242, USA.
Background/Objectives:
Despite conventional cytotoxic chemotherapy treatments, soft tissue sarcoma continues to remain a terminal diagnosis for most patients. Numerous chemotherapeutic agents have been trialed in soft tissue sarcoma, with marginal improvement in overall survival. Novel therapeutic approaches are needed to improve outcomes for this entity.
Methods:
the literature was reviewed, including a summary of pertinent adjuvant/neoadjuvant clinical trials and trials for metastatic disease.
Results:
Chemotherapeutic agent use in adjuvant/neoadjuvant trials provided limited if any evidence of the benefit of chemotherapy in this space. Despite multiple trials in the metastatic space, novel chemotherapeutic agents appear to have limited long-term benefits for the management of soft tissue sarcoma. Suggestions for further research, particularly with neoadjuvant clinical trials, were made.
Conclusions:
Chemotherapy remains an inadequate treatment option for soft tissue sarcoma, and novel therapies are needed. The neoadjuvant space provides an excellent opportunity to study the effects of innovative treatments in soft tissue sarcoma.
Insights
Conventional chemotherapy offers limited benefits for soft tissue sarcoma, a typically terminal diagnosis. Further research into novel therapies, especially in the neoadjuvant setting, is crucial for improving patient outcomes.
Area of Science:
- Oncology
- Medical Research
Background:
- Soft tissue sarcoma remains a terminal diagnosis for many patients, even with conventional cytotoxic chemotherapy.
- Existing chemotherapeutic agents have shown only marginal improvements in overall survival for soft tissue sarcoma.
Purpose of the Study:
- To review the efficacy of current and novel chemotherapeutic agents in treating soft tissue sarcoma.
- To identify areas for future research, particularly in neoadjuvant clinical trials.
Main Methods:
- A comprehensive literature review was conducted.
- Pertinent adjuvant/neoadjuvant and metastatic disease clinical trials were summarized.
Main Results:
- Chemotherapy in adjuvant/neoadjuvant settings provided minimal evidence of benefit for soft tissue sarcoma.
- Novel chemotherapeutic agents demonstrated limited long-term efficacy in metastatic soft tissue sarcoma trials.
Conclusions:
- Chemotherapy is an inadequate treatment for soft tissue sarcoma, necessitating the development of novel therapies.
- The neoadjuvant setting presents a promising opportunity to investigate innovative treatments for soft tissue sarcoma.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers
01:15Drugs that Stabilize Microtubules